ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline
- ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021.
- Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer.